Improved survival with Simendan (cas 131741-08-7) after experimental myocardial infarction in rats

Add time:07/22/2019    Source:sciencedirect.com

This study compared the effects of Simendan (cas 131741-08-7), a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction. Seven days after ligation-induced myocardial infarction, the rats were randomized to control, milrinone, enalapril, or simendan groups. All compounds were administered via the drinking water for 312 days, at which time there was 80% mortality in the control group—the study's primary endpoint. The infarct sizes were similar across all groups. At endpoint, the mortality rates were: 63% (milrinone), 56% (enalapril) and 53% (simendan); the risk reductions were 25% (P=0.04 vs. control) and 28% (P=0.02 vs. control) with enalapril and simendan, respectively. Milrinone had no statistically significant effect on the survival rate. These findings suggest that, like enalapril, simendan improved survival in rats with healed myocardial infarction.

We also recommend Trading Suppliers and Manufacturers of Simendan (cas 131741-08-7). Pls Click Website Link as below: cas 131741-08-7 suppliers

Prev:A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study
Next:Scammonins I and II, the resin glycosides of radix scammoniae from Convolvulus scammonia)